导语：“在创新药浪潮奔涌向前、竞争愈发激烈的当下，肿瘤免疫治疗领域成为各方角逐的关键战场。维立志博，作为国内创新药领域的先锋力量，其发展历程与战略布局备受瞩目。创始人康小强博士曾任职于礼来，深度参与创新药从实验室到上市的全流程，积累了丰富的全球研发经验。2014 年，在国内创新药尚处起步、生态贫瘠之时，他毅然回国创办维立志博，凭借敏锐的行业预判，避开拥挤赛道，聚焦 PD-1 未解决需求，开启差异化...
Source Link导语：“在创新药浪潮奔涌向前、竞争愈发激烈的当下，肿瘤免疫治疗领域成为各方角逐的关键战场。维立志博，作为国内创新药领域的先锋力量，其发展历程与战略布局备受瞩目。创始人康小强博士曾任职于礼来，深度参与创新药从实验室到上市的全流程，积累了丰富的全球研发经验。2014 年，在国内创新药尚处起步、生态贫瘠之时，他毅然回国创办维立志博，凭借敏锐的行业预判，避开拥挤赛道，聚焦 PD-1 未解决需求，开启差异化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.